- Home
- FBGL vs BTAI Comparison
FBGL vs BTAI Comparison
Compare FBGL & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FBGL
- BTAI
- Stock Information
- Founded
- FBGL 1996
- BTAI 2017
- Country
- FBGL Singapore
- BTAI United States
- Employees
- FBGL N/A
- BTAI N/A
- Industry
- FBGL Miscellaneous manufacturing industries
- BTAI Biotechnology: Pharmaceutical Preparations
- Sector
- FBGL Consumer Discretionary
- BTAI Health Care
- Exchange
- FBGL Nasdaq
- BTAI Nasdaq
- Market Cap
- FBGL 8.5M
- BTAI 8.3M
- IPO Year
- FBGL 2025
- BTAI 2018
- Fundamental
- Price
- FBGL $0.61
- BTAI $4.04
- Analyst Decision
- FBGL
- BTAI Buy
- Analyst Count
- FBGL 0
- BTAI 5
- Target Price
- FBGL N/A
- BTAI $34.80
- AVG Volume (30 Days)
- FBGL 135.5K
- BTAI 17.1M
- Earning Date
- FBGL 01-01-0001
- BTAI 08-15-2025
- Dividend Yield
- FBGL N/A
- BTAI N/A
- EPS Growth
- FBGL N/A
- BTAI N/A
- EPS
- FBGL N/A
- BTAI N/A
- Revenue
- FBGL $10,146,582.00
- BTAI $1,852,000.00
- Revenue This Year
- FBGL N/A
- BTAI N/A
- Revenue Next Year
- FBGL N/A
- BTAI $328.13
- P/E Ratio
- FBGL N/A
- BTAI N/A
- Revenue Growth
- FBGL N/A
- BTAI 5.47
- 52 Week Low
- FBGL $0.44
- BTAI $1.17
- 52 Week High
- FBGL $5.45
- BTAI $15.46
- Technical
- Relative Strength Index (RSI)
- FBGL N/A
- BTAI 82.77
- Support Level
- FBGL N/A
- BTAI $1.30
- Resistance Level
- FBGL N/A
- BTAI $3.84
- Average True Range (ATR)
- FBGL 0.00
- BTAI 0.50
- MACD
- FBGL 0.00
- BTAI 0.24
- Stochastic Oscillator
- FBGL 0.00
- BTAI 81.07
About FBGL FBS Global Limited Ordinary Shares
FBS Global Ltd is a green building contractor and an established interior fit-out specialist in institutional, residential, commercial, and industrial building projects. As a green contractor focused on environmentally sound practices, the company aims to bid tenders for green building projects, use green construction methods and green materials for construction projects, including design, supply and installation of ceilings, partitions, timber deck, carpet, acoustic wall paneling, built-in furniture as well as mechanical and electrical services of a building. The company's revenue is derived mainly from the construction contracts and Sales of construction materials.
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.